25 November 2019 - Approval of supplemental new drug aubmission for Adcetris in combination with CHP chemotherapy in frontline CD30-expressing peripheral ...
21 November 2019 - New indication improves overall survival for end stage metastatic disease ...
21 November 2019 - Today, as part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration and Health Canada, ...
19 November 2019 - Medexus Pharmaceuticals today announced that Health Canada has granted priority review status for the new drug ...
12 November 2019 - Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 ...
8 November 2019 - Patients experienced a 77% reduction in risk of disease progression or death compared to chlorambucil plus obinutuzumab. ...
30 October 2019 - This Darzalex combination regimen reduced the risk of disease progression or death by 44% in newly ...
15 October 2019 - Cabometyx demonstrated a statistically significant, 52% reduction in the risk of progression or death compared with sunitinib, ...
8 October 2019 - Approval of the highly selective Bruton's tyrosine kinase inhibitor in mantle cell lymphoma marks AstraZeneca's entry ...
27 September 2019 - New approval provides patients with PD-L1 positive, metastatic triple-negative breast cancer with an additional treatment option that ...
13 August 2019 - Data show Tecentriq in combination with carboplatin and etoposide helped patients with extensive-stage small cell lung ...
30 July 2019 - Bayer announced today that there is now a treatment in Canada for tyrosine receptor kinase fusion ...
16 July 2019 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) for the extended adjuvant treatment of ...
10 July 2019 - Pomalyst in combination with bortezomib and dexamethasone, provides a new medication option for patients living with multiple ...
26 June 2019 - Knight Therapeutics announced today that Knight's new drug submission for Ibsrela (tenapanor) has been accepted for ...